Credit Suisse Group downgraded shares of Mesoblast (NASDAQ:MESO) from a neutral rating to an underperform rating in a research note released on Thursday, Marketbeat Ratings reports. They currently have $6.00 price target on the stock.
A number of other brokerages have also recently issued reports on MESO. Maxim Group set a $14.00 price objective on shares of Mesoblast and gave the company a buy rating in a report on Wednesday, March 7th. Cantor Fitzgerald set a $23.00 price objective on shares of Mesoblast and gave the company a buy rating in a report on Tuesday, February 27th. Oppenheimer set a $16.00 price objective on shares of Mesoblast and gave the company a buy rating in a report on Wednesday, December 20th. Finally, Zacks Investment Research cut shares of Mesoblast from a buy rating to a hold rating in a report on Tuesday, January 23rd. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of $12.82.
Shares of Mesoblast stock opened at $5.66 on Thursday. Mesoblast has a 1 year low of $4.74 and a 1 year high of $12.50. The company has a market cap of $533.01, a P/E ratio of -15.30 and a beta of 1.83.
WARNING: “Mesoblast (MESO) Lowered to “Underperform” at Credit Suisse Group” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3299567/mesoblast-meso-lowered-to-underperform-at-credit-suisse-group.html.
Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.